AstraZeneca | GenomeWeb


The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

The test can now be used to detect EGFR mutations in tissue and blood for lung cancer patients considering treatment with the tyrosine kinase inhibiting drugs Tarceva and Tagrisso. 

The partners are working together to advance research into the role of epigenetics in respiratory diseases such as asthma and COPD.

The STARNET study found that cardiometabolic disease risk loci share cis- and trans-gene regulation.

The resource will offer easy access to an inventory of vendors with patient-derived xenograph models as well as associated molecular data for oncology drug discovery projects.

Drug developers and genetic testing firms are contemplating how best to share variant classification data while protecting their commercial interests.

Lynparza is just the start of an expansive portfolio of treatments targeting DNA damage response that AstraZeneca said it will advance with companion tests.

The assay will detect multiple classes of genomic alterations across a range of genes involved in homologous recombination repair.

The firm also said that Roche started selling FoundationOne in Israel, Austria, Germany, Switzerland, Brazil, Canada, and Singapore last month.

AstraZeneca'sVarDict was designed to more accurately identify complex tumor mutations in DNA and RNA sequencing data even in samples with low tumor content.


The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.